A new breakthrough in targeted protein degradation is reshaping the future of Alzheimer’s treatment. Researchers have developed an AI-designed PROTAC (Proteolysis Targeting Chimera) capable of selectively eliminating toxic tau protein aggregates—one of the primary drivers of neurodegeneration in Alzheimer’s disease.